Reports of Biochemistry
and Molecular Biology
Sat, Apr 20, 2024
[Archive]
Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)
rbmb.net 2022, 11(3): 394-399 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Amin R, Indiarsih T B, Sari P M, Purwanita P. Anti-RAGE (Receptor Advanced Glycation End products) Antibody Improves Diabetic Retinopathy in Rats via Hypoglycemic and
Anti-inflammatory Mechanism. rbmb.net 2022; 11 (3) :394-399
URL: http://rbmb.net/article-1-913-en.html
URL: http://rbmb.net/article-1-913-en.html
Department of Ophthalmology, Faculty of Medicine Universitas Sriwijaya/ Dr Moh Hoesin General Hospital, Palembang, Indonesia
Abstract: (2284 Views)
Background: Receptor advanced glycation end products (RAGE) activation plays an essential role in diabetic retinopathy (DR) progression. This study was aimed to explore the role of anti-RAGE antibodies (RAGE antagonists) in inhibiting DR progression through their hypoglycemic and anti inflammatory mechanism in diabetic retinopathy induced rats.
Methods: A total of 30 male Wistar rats were randomly divided into five group. The group was consisted of normal control group, DR group without treatment, DR group with anti-RAGE 1 g/kg BW, 10 g/kg BW, and 100 g/kg BW. To assess the diabetic retinopathy, fundus photographs were taken every week using a camera with 16x magnification placed in front of the rat's eyes. Blood glucose was checked by the glucose oxidase-peroxidase method. Retinal TNF- levels and VEGF were examined using an enzyme-linked immunosorbent assay (ELISA) kit.
Results: The finding of this study showed that anti-RAGE treatment at dose of 10 and 100 g/kg BW, HbA1c levels were significantly higher (p< 0.05) compared to the normal control group but significantly lower (p< 0.05) than in the diabetes group. The mean blood vessel diameter in the DR+anti-RAGE 10 and 100 g/kg BW groups was significantly lower than in the diabetic retinopathy group (p< 0.05). The administration of anti-RAGE 10 and 100 g/kg BW showed the ability to significantly reduce VEGF levels compared to the DR group (p< 0.05).
Conclusions:This study revealed at doses of 10 and 100 g/kg BW, anti-RAGE antibodies improved diabetic retinopathy in Wistar rats through hypoglycemic effects and anti-inflammatory mechanisms.
Keywords: Anti-RAGE (Receptor Advanced Glycation End products), Diabetic Retinopathy, Glycated Hemoglobin A, Hypoglycemic Agents, Peroxidases, Vascular Endothelial Growth Factor A
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2022/04/12 | Accepted: 2022/04/21 | Published: 2022/12/31
Received: 2022/04/12 | Accepted: 2022/04/21 | Published: 2022/12/31
References
1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (London). 2015;2:17. [DOI:10.1186/s40662-015-0026-2] [PMID] [PMCID]
2. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21. [DOI:10.1007/s11886-019-1107-y] [PMID]
3. Endris T, Worede A, Asmelash D. Prevalence of diabetes mellitus, prediabetes and its associated factors in Dessie Town, Northeast Ethiopia: A community-based study. Diabetes Metab Syndr Obes. 2019;12:2799-2809. [DOI:10.2147/DMSO.S225854] [PMID] [PMCID]
4. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxid Med Cell Longev. 2015;2015:610813. [DOI:10.1155/2015/610813] [PMID] [PMCID]
5. Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942. [DOI:10.3390/ijms19040942] [PMID] [PMCID]
6. Zhang W, Chen S, Liu ML. Pathogenic roles of microvesicles in diabetic retinopathy. Acta Pharmacol Sin. 2018;39(1):1-11. [DOI:10.1038/aps.2017.77] [PMID] [PMCID]
7. Amin R, Ansyori AK, Erna R, Fauzi L. Anti-receptor advanced glycation end products decreases inflammatory pathways in retinopathy diabetics: in vivo study. Open Access Macedonian Journal of Medical Sciences. 2020;8A:414-417. [DOI:10.3889/oamjms.2020.4293]
8. Snelson M, Lucut E, Coughlan MT. The role of AGE-RAGE as a modulator of gut permeability in diabetes. Int J Mol Sci. 2022;23(3): 1776. [DOI:10.3390/ijms23031766] [PMID] [PMCID]
9. Serban AI, Stanca L, Geicu OI, Dinischiotu A. AGEs-induced IL-6 synthesis precedes RAGE up-regulation in HEK 293 cells: an alternative inflammatory mechanism?. Int J Mol Sci. 2015;16(9):20100-17. [DOI:10.3390/ijms160920100] [PMID] [PMCID]
10. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-94. [DOI:10.1111/j.1476-5381.2012.01911.x] [PMID] [PMCID]
11. Vucetic M, Jensen PK, Jansen EC. Diameter variations of retinal blood vessels during and after treatment with hyperbaric oxygen. Br J Ophthalmol. 2004;88(6):771-5. [DOI:10.1136/bjo.2003.018788] [PMID] [PMCID]
12. NIH (National Institute of Health). Principles of laboratory animal care. Bethesda, MD. National Institute of Health, 1985; 1-96.
13. Chandra S, Sheth J, Anantharaman G, Gopalakrishnan M. Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration. Am J Ophthalmol Case Rep. 2018;9:41-44. [DOI:10.1016/j.ajoc.2018.01.006] [PMID] [PMCID]
14. Cen S, Hsu Y, Lin Y, Huang YC, Chen CJ, Lin WD, et al. Current concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan. Biomedicine (Taipei). 2016;6(2):7. [DOI:10.7603/s40681-016-0007-3] [PMID] [PMCID]
15. Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: Breaking the barrier. Pathophysiology. 2017;24(4):229-241. [DOI:10.1016/j.pathophys.2017.07.001] [PMID] [PMCID]
16. Cheung CY, Ikram MK, Sabanagayam C, Wong TY. Retinal microvasculature as a model to study the manifestations of hypertension. Hypertension. 2012;60:1094-103. [DOI:10.1161/HYPERTENSIONAHA.111.189142] [PMID]
17. Song P, Yu J, Chan KY, Theodoratou E, Rudan I. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018;8(1):010803.
https://doi.org/10.7189/jogh.08.010803 [DOI:10.7189/jogh.08.010804] [PMID] [PMCID]
18. Sasongko MB, Widyaputri F, Agni AN, Wardhana FS, Kotha S, Gupta P, et al. Prevalence of diabetic retinopathy and blindness in Indonesian adults with type 2 diabetes. Am J Ophthalmol. 2017;181:79-87. [DOI:10.1016/j.ajo.2017.06.019] [PMID]
19. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217-233. [DOI:10.1038/nrrheum.2017.22] [PMID] [PMCID]
20. Liu L, Zuo Z, Lu S, Liu A, Liu X. Naringin attenuates diabetic retinopathy by inhibiting inflammation, oxidative stress and NF-κB activation in vivo and in vitro. Iran J Basic Med Sci. 2017;20(7):813-821.
21. Feng Y, Gross S, Chatterjee A, Wang Y, Lin J, Hammes HP. Transcription of inflammatory cytokine TNFα is upregulated in retinal angiogenesis under hyperoxia. Cell Physiol Biochem. 2016;39(2):573-83. [DOI:10.1159/000445649] [PMID]
22. Atli H, Onalan E, Yakar B, Duzenci D, Dönder E. Predictive value of inflammatory and hematological data in diabetic and non-diabetic retinopathy. Eur Rev Med Pharmacol Sci. 2022;26(1):76-83.
23. Ahuja S, Saxena S, Akduman L, Meyer CH, Kruzliak P, Khanna VK. Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. Int J Retina Vitreous. 2019;5:29. [DOI:10.1186/s40942-019-0179-6] [PMID] [PMCID]
24. Simo R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37(4):893-9. [DOI:10.2337/dc13-2002] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
